ConvaTec Group PLC Update Statement following AGM Voting Outcome (6744S)
07 Novembre 2019 - 3:00PM
UK Regulatory
TIDMCTEC
RNS Number : 6744S
ConvaTec Group PLC
07 November 2019
Update Statement following AGM Voting Outcome
7 November 2019 (LSE: CTEC)
Reading, United Kingdom 7 November 2019
At the Annual General Meeting ("AGM") of ConvaTec Group Plc
("ConvaTec" or "Company") held on 9 May 2019, 20 per cent or more
of the votes were cast against Resolution 2 to approve the
Directors' Remuneration Report. In the announcement released
immediately following the AGM, the Board outlined the actions that
it intended to take to understand and address shareholder concerns
and an update is provided below.
Naturally, the Board was disappointed with the overall outcome
of 61.55% votes in favour of the 2018 Directors' Remuneration
Report. The Company had engaged in a dialogue with a number of
shareholders and voting advisory agencies to discuss their
questions and concerns in advance of the vote at the AGM.
Following the AGM, the Remuneration Chair consulted further with
shareholders and offered to meet with them to discuss their views
and concerns where applicable. The Remuneration Committee welcomed
the feedback received from this process, and has been taking this
into consideration in its ongoing review of the Remuneration Policy
("Policy") which, in line with the Companies Act 2006, will be put
to shareholders at the Company's 2020 AGM.
The Remuneration Committee continues to evaluate the most
appropriate structure for executive director remuneration with
regards to; long-term incentive measures, value of awards made,
annual bonus measures and salary levels, to ensure that executive
director remuneration continues to be aligned with shareholder
interests. The Remuneration Committee will be consulting further
with shareholders and voting advisory agencies on the Policy in the
coming weeks to gain feedback and comments on its proposals. A
final draft of the Policy will be included in the next Annual
Report.
About ConvaTec
ConvaTec is a global medical products and technologies company
focused on therapies for the management of chronic conditions, with
leading market positions in advanced wound care, ostomy care,
continence and critical care, and infusion devices. ConvaTec's
products provide a range of clinical and economic benefits
including infection prevention, protection of at-risk skin,
improved patient outcomes and reduced total cost of care. To learn
more about ConvaTec, please visit www.convatecgroup.com where a
copy of this announcement can also be found.
Enquiries
Analysts and Investors
Mark Reynolds, Director Investor Relations +44 (0) 7551 036 625
investorrelations@convatec.com
Media
Buchanan +44 (0)207 466 5000
Charles Ryland/Chris Lane/Vicky Hayns
LEI: 213800LS272L4FIDOH92
# # #
END
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCFSEFFWFUSEIF
(END) Dow Jones Newswires
November 07, 2019 09:00 ET (14:00 GMT)
Grafico Azioni Convatec (LSE:CTEC)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Convatec (LSE:CTEC)
Storico
Da Apr 2023 a Apr 2024